Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10867328 | 1.00 | SIGMAR1 (0.66) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL5630517 | 0.88 | SIGMAR1 (0.62) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL5630513 | 0.88 | SIGMAR1 (0.62) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL6350297 | 0.85 | SIGMAR1 (0.59) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL6478894 | 0.85 | SIGMAR1 (0.59) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL3174438 | 0.84 | OPRK1 (0.58) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL10801595 | 0.84 | SIGMAR1 (0.58) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL11060007 | 0.81 | SIGMAR1 (0.55) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL7219461 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL7218504 | 0.80 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003526594-A | — | — | 2003-09-09 | — | — | JP | claimed |
| EP-0996434-A4 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | ADOLOR CORP (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0996434-A1 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | Adolor Corporation (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999003459-A1 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| US-7652025-B2 | Remedies for sepsis | TORAY INDUSTRIES, INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20040147536-A1 | Remedies for sepsis | TORAY INDUSTRIES, INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1402899-A1 | REMEDIES FOR SEPSIS | TORAY INDUSTRIES, INC. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-0996434-A4 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | ADOLOR CORP (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6156769-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | APOLOR CORP. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0996434-A1 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | Adolor Corporation (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6048860-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | ADOLOR CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| US-6004964-A | ADMINISTERING AMIDE OR SULFONAMIDE DERIVATIVE; ANALGESICS | ADOLOR CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5869521-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | ADOLOR CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1999003459-A1 | KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5760023-A | CYCLOHEXYLACETAMIDE DERIVATIVES, AGONIST AT KAPPA OPIOD RECEPTORS, TREATMENT OF ITCHING | ADOLOR CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-4618621-A | SUBSTITUTED CYCLOHEXYLBENZENEACETAMIDE | THE UPJOHN COMPANY (US) | 1986-10-21 | — | — | US | disclosed |
| EP-0176309-A2 | Use of N-(2-aminocyclohexyl)benzeneacetamides in the treatment of cerebral ischemia | THE UPJOHN COMPANY (US) | 1986-04-02 | — | — | EP | disclosed |
| US-4463013-A | Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs | THE UPJOHN COMPANY (US) | 1984-07-31 | — | — | US | disclosed |
| US-4145435-A | 2-AMINOCYCLOALIPHATIC AMIDE COMPOUNDS | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147536-A1 | Remedies for sepsis | OPRM1, OPRK1, OPRD1 | SIGMAR1 41/4885CYP3A4 123/4885CYP2D6 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.